Gut inflammation and dysbiosis in human motor neuron disease

Physiological Reports

Volumn 5, Issue 18, 2017, Pages

  Rowin, Julie ^a   Xia, Yinglin ^b   Jung, Barbara ^b   Sun, Jun ^b  

^a Wellness and Integrative Neurology   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

ALS; Bacteria; Dysbiosis; Inflammation; Microbiome; Motor neuron disease

Indexed keywords

CALGRANULIN; EOSINOPHIL PROTEIN X; SECRETORY IMMUNOGLOBULIN; SHORT CHAIN FATTY ACID;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BACTERIUM CULTURE; BACTEROIDETES; CLINICAL ARTICLE; DIGESTIVE SYSTEM INFLAMMATION; DYSBIOSIS; ENZYME IMMUNOASSAY; FECES ANALYSIS; FEMALE; FIRMICUTES; FUNGUS CULTURE; HUMAN; INTESTINE FLORA; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MICROBIAL DIVERSITY; MIDDLE AGED; MOTOR NEURON DISEASE; POLYMERASE CHAIN REACTION; RUMINOCOCCUS; VERY ELDERLY; COMPLICATION; INFLAMMATORY BOWEL DISEASE; ISOLATION AND PURIFICATION; MICROBIOLOGY;

ADULT; AGED; AGED, 80 AND OVER; AMYOTROPHIC LATERAL SCLEROSIS; BACTEROIDETES; DYSBIOSIS; FEMALE; GASTROINTESTINAL MICROBIOME; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; RUMINOCOCCUS;

EID: 85030106817     PISSN: None     EISSN: 2051817X     Source Type: Journal    
DOI: 10.14814/phy2.13443     Document Type: Article

References (23)

1. Bhattacharjee, S., and W. J. Lukiw. 2013. Alzheimer’s disease and the microbiome. Front Cell Neurosci. 7:153.
2. Collins, S. M. 2014. A role for the gut microbiota in IBS. Nat. Rev. Gastroenterol. Hepatol. 11:497-505.
3. Fang, X., X. Wang, S. Yang, F. Meng, X. Wang, H. Wei, et al. 2016. Evaluation of the microbial diversity in amyotrophic lateral sclerosis using high-throughput sequencing. Front. Microbiol. 7:1479.
4. Forshew, D. A., and M. B. Bromberg. 2003. A survey of clinicians’ practice in the symptomatic treatment of ALS. Amyotroph Lateral Scler Other Motor Neuron Disord. 4:258-263.
5. Forsyth, C. B., K. M. Shannon, J. H. Kordower, R. M. Voigt, M. Shaikh, J. A. Jaglin, et al. 2011. Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson’s disease. PLoS ONE 6:e28032.
6. Hsiao, E. Y., S. W. McBride, S. Hsien, G. Sharon, E. R. Hyde, T. McCue, et al. 2013. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell 155:1451-1463.
7. Kouchaki, E., O. R. Tamtaji, M. Salami, F. Bahmani, R. Daneshvar Kakhaki, E. Akbari, et al. 2017. Clinical and metabolic response to probiotic supplementation in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled trial. Clin. Nutr. 36:1245-1249.
8. Miller, R. G., C. E. Jackson, E. J. Kasarskis, J. D. England, D. Forshew, W. Johnston, et al. 2009. Woolley SC and Quality Standards Subcommittee of the American Academy of N. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 73:1227-1233.
9. Mosca, A., M. Leclerc, and J. P. Hugot. 2016. Gut microbiota diversity and human diseases: should we reintroduce key predators in our ecosystem? Front. Microbiol. 7:455.
10. de Oliveira, G. L. V., A. Z. Leite, B. S. Higuchi, M. I. Gonzaga, and V. S. Mariano. 2017. Intestinal dysbiosis and probiotic applications in autoimmune diseases. Immunology 152:1-12.
11. Rentzos, M., A. Rombos, C. Nikolaou, M. Zoga, V. Zouvelou, A. Dimitrakopoulos, et al. 2010. Interleukin-17 and interleukin-23 are elevated in serum and cerebrospinal fluid of patients with ALS: a reflection of Th17 cells activation? Acta Neurol. Scand. 122:425-429.
12. Sampson, T. R., J. W. Debelius, T. Thron, S. Janssen, G. G. Shastri, Z. E. Ilhan, et al. 2016. Gut microbiota regulate motor deficits and neuroinflammation in a model of parkinson’s disease. Cell 167(1469-1480):e12.
13. Sun, J. 2017. Commentary: target intestinal microbiota to alleviate disease progression in amyotrophic lateral sclerosis. J Neurol Neuromed 2:13-15.
14. Sun, J., and E. B. Chang. 2014. Exploring gut microbes in human health and disease: pushing the envelope. Genes Dis. 1:132-139.
15. Sun, J., and J. Zhou. 2015. Does the gut drive ALS progression? Future Medicine. 5:375-378.
16. Tamboli, C. P., C. Neut, P. Desreumaux, and J. F. Colombel. 2004. Dysbiosis in Inflammatory Bowel Disease. Gut. 53:1-4.
17. Toepfer, M., C. Folwaczny, A. Klauser, R. L. Riepl, W. Muller-Felber, and D. Pongratz. 1999. Gastrointestinal dysfunction in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 1:15-19.
18. Walsham, N. E., and R. A. Sherwood. 2016. Fecal calprotectin in inflammatory bowel disease. Clin. Exp. Gastroenterol. 9:21-29.
19. Wu, S., J. Yi, Y. G. Zhang, J. Zhou, and J. Sun. 2015a. Leaky intestine and impaired microbiome in an amyotrophic lateral sclerosis mouse model. Physiol. Rep. 3: pii: e12356.
20. Wu, S., Y. G. Zhang, R. Lu, Y. Xia, D. Zhou, E. O. Petrof, et al. 2015b. Intestinal epithelial vitamin D receptor deletion leads to defective autophagy in colitis. Gut 64:1082-1094.
21. Xia, Y., and J. Sun. 2017. Statistical Models and Analysis of Microbiome Data from Mice and Human. in J. Sun, P. Dudeja, eds. Mechanisms underlying host-microbiome interactions in pathophysiology of human diseases. Series title: Physiology in Health and Disease. APS E-Book, Springer Nature, New York. In press.
22. Zhang, R., R. G. Miller, R. Gascon, S. Champion, J. Katz, M. Lancero, et al. 2009. Circulating endotoxin and systemic immune activation in sporadic amyotrophic lateral sclerosis (sALS). J. Neuroimmunol. 206:121-124.
23. Zhang, Y. G., S. Wu, J. Yi, Y. Xia, D. Jin, J. Zhou, et al. 2017. Target Intestinal microbiota to alleviate disease progression in amyotrophic lateral sclerosis. Clin. Ther. 39:322-336.